Remove Dermatitis Remove Pharmaceutical Remove Treatments
article thumbnail

JNJ Continues to Grow AD Pipeline With New Licensing Agreement

The Dermatology Digest

Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical.

article thumbnail

Derm-Biome Adds Dr. Jerry Tan to Its Scientific Advisory Board

The Dermatology Digest

Jerry Tan, MD, is joining Derm-Biome Pharmaceuticals, Inc.’s Acne is a very common skin disease, but there is still a real unmet need for treatments that are both well-tolerated and effective. s Scientific Advisory Board.

article thumbnail

Weighing Risks Vs. Benefits of Systemic AD Treatments

The Dermatology Digest

Shared-decision making focused on weighing risks versus benefits is key when choosing the most appropriate systemic atopic dermatitis (AD) treatment for a patient, according to new research presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC. some of the JAK inhibitors).

article thumbnail

Oh, What a Year! The Skin of Color Society Reflects on Its Dynamic 2024

The Dermatology Digest

Alexis and Kwatra “Seborrheic Dermatitis in Skin of Color” with Drs. The 20th Annual SOCS Scientific Symposium was generously supported by the following sponsors: AbbVie, Johnson & Johnson, Sanofi and Regeneron Pharmaceuticals, Inc. Adotama and Luke “A Fresh Look at Aging” with Drs.

Webinar 78
article thumbnail

There’s Something About Eblasakimab: Aslan, Zenyaku Partner to Investigate How it Differs From Other Biologics for AD

The Dermatology Digest

Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD). This new agreement expands upon the commercial agreement that Aslan signed with Zenyaku in June 2023 for the development and commercialization of eblasakimab in Japan.

article thumbnail

Off-label Pearl: Exploring the Role of Narrowband UVB Phototherapy Plus Oral JAK Inhibitors in Vitiligo

The Dermatology Digest

Adding narrowband ultraviolet B phototherapy to treatment with ritlecitinib (Litfulo, Pfizer) in vitiligo may improve patient outcomes. Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Watch Now The Lowdown on Molluscum Nanette B.

article thumbnail

LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Hit Higher Treatment Targets

The Dermatology Digest

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. Both groups had similar proportions of patients with treatment-emergent adverse events (TEAEs).